Study Group: Astelin Prescribers (US)
Council Members in this Study Group: 39
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Mitchell Boxer
Assistant Clinical Professor
Albert Einstein College of Medicine
Mitchell Boxer, MD, is Director of the Adult Allergy Section at Long Island Jewish Medical Center and Assistant Clinical Professor at Albert Einstein Medical College. He also runs his own private practice. Dr. Boxer completed his fellowship at Northwestern...
David EnglerPhysician
The Allergy ClinicDavid Engler, MD, a graduate of Baylor College of Medicine, has worked at The Allergy Clinic since 1991. He has served two terms on the Board of Regents of the American College of Allergy, Asthma & Immunology, and has represented that organization at...
Dean TraigerPhysician
Physicians’ Primary Care of Southwest Florida,P.L.Dean Traiger, MD, is the Owner of Physician's Primary Care of Southwest Florida. Dr. Traiger is board certified in Family Practice and specializes in general primary care across the continuum of pediatrics, adolescent, and adult and geriatric care. He...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
They'll fix this before the end of the month
July 2, 2008
Analysis by: David Engler, Physician,Medicare fees to doctors fall Tuesday | news.yahoo.com
If this isn't fixed, it won't be long before cognitive specialties, like internal medicine and neurology, start capping their practices and not allowing new Medicare patients.
-
This may have a market after all
July 2, 2008
Analysis by: David Engler, Physician,Taro Receives Final FDA Approval For RX Cetirizine Hydrochloride Syrup ANDA | www.medicalnewstoday.com
Here comes a prescription version of generic Zyrtec syrup. At first glance, we wonder how it will compete with over the counter Zyrtec. But wait...there may be a market for this drug
-
Next-Generation Xolair (omalizumab) sounds pretty good
June 18, 2008
Analysis by: David Engler, Physician,Investigational Anti-IgE Antibody Promising as Extracorporeal Allergy Therapy | www.medscape.com
This drug seems much more effective at reducing free-IgE levels than is Xolair. Overall, Xolair has given many patients a tremendous improvement in their quality of life, but it hasn't fulfilled many of its promises. Frankly, some of Xolair's benefits are disappointing, particularly in the 40 or 50% of patients who use it without achieving great results. In particular, Xolair patients who are on Advair 500/50 can sometimes get down to Advair 250/50, but it's been difficult tapering them to lower doses of inhaled corticosteroids.
-
April 4, 2008
Analysis by: David Engler, Physician,New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
A bottle of 30 Generic Zyrtec can be purchased for $15. No one is going to get Xyzal that inexpensively. There are no head to head studies showing Xyzal to be better than Zyrtec. Even though Xyzal claims a 6% sedation rate compared to Zyrtec's 14% rate, it's not apples to apples. In the Zyrtec study, placebo made 8% sleepy, whereas placebo only made 2% sleepy in the Xyzal study. Thus, either way, the drug was much more sedating than the placebo.
-
Slowly but surely, Primary Care gets the message about preventing asthma
April 4, 2008
Analysis by: David Engler, Physician,FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 | www.pipelinereview.com
Use of Asmanex will continue to increase with this approval down to age 4. Its dose counter tells you exactly how many doses are left in the device. Pulmicort uses a system that counts down 120---90---60---30---0. A lot of patients on Pulmicort complain to me about this "approximate" dose counter. Also, Asmanex is easier to use than Pulmicort , but you get less for your money. Pulmicort 180 gives you 120 doses in each cannister; Asmanex only gives you 30 or 60. Therefore, a Pulmicort prescription will last a patient two months unless they're taking 4 puffs per day. With the recent possible bad news about Singulair and suicide, parents may be less hesitant to try inhaled steroids. Especially if their child with asthma already has a brittle psychiatric history.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- President
- Physician - Director
- Partner
- Director
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Allergists (US) | 419 |
| Physicians who Treat Asthma (US) | 610 |
| Pulmonologists (US) | 759 |
| Xolair Prescribers for Asthma (US) | 75 |
| Immunologists (US) | 384 |
| Physicians in the U.S. who Treat Chronic Obstructive Pulmonary Disease (COPD) | 375 |
| Asmanex Twisthaler Prescribers (US) | 21 |
| Nasonex Prescribers (US) | 21 |